This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no benefit for the anti-inflammatory drug in patients post MI.
Medscape Medical News